Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Not applicable

Implantable Brain-Computer Interface for Upper-Limb Recovery After Stroke

NCT07477613 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2026-04-08
Last updated
2026-07-07

Condition(s) studied

Stroke

Investigational drug(s) / intervention(s)

BCI

BCI: WIMAGINE

Study summary

The clinical investigation will take place in three phases:

* A pre-selection/selection phase to ensure that the patient (lesion, symptoms, ability of our tools to detect your movement intentions, etc.) is suitable for a six-month intensive rehabilitation program using Brain-Machine Interface.
* A second phase, consisting of implementing the intensive rehabilitation program, first in the traditional manner, without the Brain-Machine Interface (2 to 5 weeks), then, after implantation, with the Brain-Machine Interface (6 months).
* During the third phase, only follow-up visits will be scheduled to ensure the longevity of the implants and the maintenance of the motor progress achieved through rehabilitation.

Eligibility

Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria: 1. Male or female, 18-70 years-old included 2. Hemispheric ischemic stroke (\> 1.5 cm on 2 imaging slices): cortical and/or subcortical lesion 3. No decompressive craniectomy procedure performed 4. Single unilateral stroke occurred 6 months to 18 months ago 5. Disabling motor deficit of upper limb 6. Patient able to follow a rehabilitation program 7. Written consent to participate in the study from the patient and his/her legal representative 8. Person affiliated to the social security system or beneficiary of such a system 9. Highly effective or at least acceptable birth control method for women of childbearing potential Exclusion Criteria: 1. Contraindication for Magnetic Resonance Imaging (MRI), Computed Tomography (CT-scan), Positron Emission Tomography (PET-scan) 2. Contraindication for Transcranial Magnetic Stimulation (TMS), Electroencephalography (EEG), Magnetoencephalography (MEG) 3. Contraindication for general anesthesia and for the surgery (such as thrombocytopenia, …) 4. Severe leukoaraiosis 5. Previous stroke (symptomatic deficit) 6. Pre-existing dementia or significant cognitive deficits (MoCA) 7. Intolerance to electrical stimulation 8. Major spasticity in the upper limb (4 or 5 in the scale of Modified Ashworth Scale - MAS) 9. Lesions on the scalp area, skin infections or dermatitis 10. Epileptiform focus, even without clinical repercussions 11. A health status, any clinical condition (eg, short life expectancy, and coexisting disease) or other characteristic that precludes appropriate diagnosis, treatment, or follow-up in the trial 12. Presence of brain implants of metal clips and/or brain stimulators 13. Severe dystonia/involuntary movements Patients with any of the following criteria cannot be included in this investigation: 1. Contraindication for MRI, CT-scan, PET-scan 2. Contraindication for TMS, EEG, MEG 3. Contraindication for general anesthesia and for the surgery (such as thrombocytopenia, …) 4. Severe leukoaraiosis 5. Previous stroke (symptomatic deficit) 6. Pre-existing dementia or significant cognitive deficits (MoCA) 7. Intolerance to electrical stimulation 8. Major spasticity in the upper limb (4 or 5 in the scale of Modified Ashworth Scale - MAS) 9. Lesions on the scalp area, skin infections or dermatitis 10. Epileptiform focus, even without clinical repercussions 11. A health status, any clinical condition (eg, short life expectancy, and coexisting disease) or other characteristic that precludes appropriate diagnosis, treatment, or follow-up in the trial 12. Presence of brain implants of metal clips and/or brain stimulators 13. Severe dystonia/involuntary movements 14. Persons referred to in Articles L1121-5 to L1121-7 of the French Public Health Code (CSP), corresponding to all protected persons: pregnant women, women in labor, breastfeeding mothers, individuals deprived of liberty by judicial or administrative decision, individuals undergoing psychiatric care under Articles L.3212-1 and L.3213-1 who are not covered by Article L.1121-8, individuals admitted to a healthcare or social institution for purposes other than research, and minors. Moreover, patient will not be included for implantation (exclusion criteria), if he is not eligible for a BCI rehabilitation protocol, as determined by the clinical team after multimodal selection tests. As examples, it can be due to: 1. No existing residual corticospinal tracts proven tractography and/or Motor Evoked Potential (MEP) 2. Unability to control a BCI or unwillingness to follow a BCI rehabilitation program, assessed by MEG-BCI 3. Unability to activate any residual motor regions during motor imagery assessed by EEG and functional MRI (fMRI) 4. Shape of the skull in the implantation site not concordant with the WIMAGINE implant, assessed by anatomical MRI

Primary outcome measure(s)

  • Safety of a wireless ECoG-based BCI using WIMAGINE® system in stroke patients — 2 years after surgery
    Serious adverse events associated with the chronic implantation of an extradural ECoG measuring implant

Trial sites (1)

FacilityCityRegionStatus
CHUGA Grenoble France Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07477613 on ClinicalTrials.gov ↗ ← All trials in France